nodes	percent_of_prediction	percent_of_DWPC	metapath
Zafirlukast—ABCG2—Teniposide—lymphatic system cancer	0.157	0.196	CbGbCtD
Zafirlukast—ABCG2—Mitoxantrone—lymphatic system cancer	0.11	0.137	CbGbCtD
Zafirlukast—CYP1A2—Carmustine—lymphatic system cancer	0.0964	0.12	CbGbCtD
Zafirlukast—CYP2E1—Mitoxantrone—lymphatic system cancer	0.0783	0.0979	CbGbCtD
Zafirlukast—ABCG2—Vincristine—lymphatic system cancer	0.0756	0.0945	CbGbCtD
Zafirlukast—CYP2C19—Teniposide—lymphatic system cancer	0.0702	0.0877	CbGbCtD
Zafirlukast—CYP2C9—Teniposide—lymphatic system cancer	0.0584	0.0729	CbGbCtD
Zafirlukast—ABCG2—Methotrexate—lymphatic system cancer	0.0458	0.0572	CbGbCtD
Zafirlukast—CYP3A4—Cytarabine—lymphatic system cancer	0.0345	0.0431	CbGbCtD
Zafirlukast—CYP3A4—Teniposide—lymphatic system cancer	0.0339	0.0424	CbGbCtD
Zafirlukast—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0237	0.0297	CbGbCtD
Zafirlukast—CYP3A4—Vincristine—lymphatic system cancer	0.0163	0.0204	CbGbCtD
Zafirlukast—Raised liver function tests—Teniposide—lymphatic system cancer	0.00633	0.0317	CcSEcCtD
Zafirlukast—Blister—Mechlorethamine—lymphatic system cancer	0.0055	0.0275	CcSEcCtD
Zafirlukast—Digestion impaired—Fludarabine—lymphatic system cancer	0.00384	0.0192	CcSEcCtD
Zafirlukast—Haemoptysis—Fludarabine—lymphatic system cancer	0.00347	0.0174	CcSEcCtD
Zafirlukast—Numbness—Fludarabine—lymphatic system cancer	0.0031	0.0155	CcSEcCtD
Zafirlukast—Dermatitis bullous—Mechlorethamine—lymphatic system cancer	0.00301	0.0151	CcSEcCtD
Zafirlukast—Sensory loss—Fludarabine—lymphatic system cancer	0.00296	0.0148	CcSEcCtD
Zafirlukast—Neuropathy—Teniposide—lymphatic system cancer	0.00274	0.0137	CcSEcCtD
Zafirlukast—Hepatic function abnormal—Teniposide—lymphatic system cancer	0.00243	0.0121	CcSEcCtD
Zafirlukast—Jaundice—Mechlorethamine—lymphatic system cancer	0.00216	0.0108	CcSEcCtD
Zafirlukast—Hepatotoxicity—Carmustine—lymphatic system cancer	0.00213	0.0107	CcSEcCtD
Zafirlukast—Hepatic failure—Fludarabine—lymphatic system cancer	0.00207	0.0104	CcSEcCtD
Zafirlukast—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.00207	0.0104	CcSEcCtD
Zafirlukast—Haemoglobin—Mechlorethamine—lymphatic system cancer	0.002	0.01	CcSEcCtD
Zafirlukast—Haemorrhage—Mechlorethamine—lymphatic system cancer	0.00199	0.00996	CcSEcCtD
Zafirlukast—Liver function test abnormal—Teniposide—lymphatic system cancer	0.00196	0.0098	CcSEcCtD
Zafirlukast—Numbness—Vincristine—lymphatic system cancer	0.00189	0.00947	CcSEcCtD
Zafirlukast—Accidental injury—Carmustine—lymphatic system cancer	0.00186	0.00929	CcSEcCtD
Zafirlukast—Sensory loss—Vincristine—lymphatic system cancer	0.00181	0.00906	CcSEcCtD
Zafirlukast—Contusion—Mitoxantrone—lymphatic system cancer	0.00175	0.00876	CcSEcCtD
Zafirlukast—Liver function test abnormal—Fludarabine—lymphatic system cancer	0.00172	0.00861	CcSEcCtD
Zafirlukast—Neutropenia—Teniposide—lymphatic system cancer	0.00171	0.00858	CcSEcCtD
Zafirlukast—Raised liver function tests—Methotrexate—lymphatic system cancer	0.00165	0.00825	CcSEcCtD
Zafirlukast—Neuropathy peripheral—Teniposide—lymphatic system cancer	0.0016	0.00802	CcSEcCtD
Zafirlukast—Leukocytoclastic vasculitis—Methotrexate—lymphatic system cancer	0.00155	0.00777	CcSEcCtD
Zafirlukast—Neuropathy—Carmustine—lymphatic system cancer	0.00154	0.00772	CcSEcCtD
Zafirlukast—Neutropenia—Fludarabine—lymphatic system cancer	0.00151	0.00754	CcSEcCtD
Zafirlukast—Injury—Bleomycin—lymphatic system cancer	0.00149	0.00744	CcSEcCtD
Zafirlukast—Haemoglobin—Teniposide—lymphatic system cancer	0.00147	0.00738	CcSEcCtD
Zafirlukast—Neuropathy—Vincristine—lymphatic system cancer	0.00147	0.00737	CcSEcCtD
Zafirlukast—Haemorrhage—Teniposide—lymphatic system cancer	0.00147	0.00734	CcSEcCtD
Zafirlukast—Neuropathy peripheral—Fludarabine—lymphatic system cancer	0.00141	0.00705	CcSEcCtD
Zafirlukast—Infection—Mechlorethamine—lymphatic system cancer	0.0014	0.00703	CcSEcCtD
Zafirlukast—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00138	0.00693	CcSEcCtD
Zafirlukast—Swelling—Carmustine—lymphatic system cancer	0.00135	0.00677	CcSEcCtD
Zafirlukast—Sinusitis—Fludarabine—lymphatic system cancer	0.00135	0.00674	CcSEcCtD
Zafirlukast—Injury—Carmustine—lymphatic system cancer	0.0013	0.00649	CcSEcCtD
Zafirlukast—Haemoglobin—Fludarabine—lymphatic system cancer	0.0013	0.00649	CcSEcCtD
Zafirlukast—Haemorrhage—Fludarabine—lymphatic system cancer	0.00129	0.00645	CcSEcCtD
Zafirlukast—Hypoaesthesia—Fludarabine—lymphatic system cancer	0.00128	0.00642	CcSEcCtD
Zafirlukast—Hepatic failure—Vincristine—lymphatic system cancer	0.00127	0.00634	CcSEcCtD
Zafirlukast—Swelling—Mitoxantrone—lymphatic system cancer	0.00126	0.00629	CcSEcCtD
Zafirlukast—Liver function test abnormal—Carmustine—lymphatic system cancer	0.0011	0.00551	CcSEcCtD
Zafirlukast—Haematemesis—Methotrexate—lymphatic system cancer	0.0011	0.00548	CcSEcCtD
Zafirlukast—Oedema—Teniposide—lymphatic system cancer	0.00104	0.00522	CcSEcCtD
Zafirlukast—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00104	0.00521	CcSEcCtD
Zafirlukast—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00104	0.00521	CcSEcCtD
Zafirlukast—Infection—Teniposide—lymphatic system cancer	0.00104	0.00518	CcSEcCtD
Zafirlukast—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00102	0.00511	CcSEcCtD
Zafirlukast—Malaise—Fludarabine—lymphatic system cancer	0.00101	0.00507	CcSEcCtD
Zafirlukast—Pruritus—Mechlorethamine—lymphatic system cancer	0.001	0.00501	CcSEcCtD
Zafirlukast—Hepatotoxicity—Methotrexate—lymphatic system cancer	0.000986	0.00493	CcSEcCtD
Zafirlukast—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.000968	0.00484	CcSEcCtD
Zafirlukast—Neutropenia—Carmustine—lymphatic system cancer	0.000964	0.00482	CcSEcCtD
Zafirlukast—Arthralgia—Fludarabine—lymphatic system cancer	0.000956	0.00478	CcSEcCtD
Zafirlukast—Myalgia—Fludarabine—lymphatic system cancer	0.000956	0.00478	CcSEcCtD
Zafirlukast—Haemoglobin—Bleomycin—lymphatic system cancer	0.00095	0.00476	CcSEcCtD
Zafirlukast—Haemorrhage—Bleomycin—lymphatic system cancer	0.000946	0.00473	CcSEcCtD
Zafirlukast—Discomfort—Fludarabine—lymphatic system cancer	0.000944	0.00473	CcSEcCtD
Zafirlukast—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.000941	0.00471	CcSEcCtD
Zafirlukast—Neutropenia—Vincristine—lymphatic system cancer	0.000921	0.00461	CcSEcCtD
Zafirlukast—Oedema—Fludarabine—lymphatic system cancer	0.000916	0.00458	CcSEcCtD
Zafirlukast—Infection—Fludarabine—lymphatic system cancer	0.00091	0.00455	CcSEcCtD
Zafirlukast—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.000901	0.00451	CcSEcCtD
Zafirlukast—Vomiting—Mechlorethamine—lymphatic system cancer	0.000899	0.0045	CcSEcCtD
Zafirlukast—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.000897	0.00449	CcSEcCtD
Zafirlukast—Neutropenia—Mitoxantrone—lymphatic system cancer	0.000896	0.00449	CcSEcCtD
Zafirlukast—Rash—Mechlorethamine—lymphatic system cancer	0.000892	0.00446	CcSEcCtD
Zafirlukast—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000891	0.00446	CcSEcCtD
Zafirlukast—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00086	0.0043	CcSEcCtD
Zafirlukast—Feeling abnormal—Teniposide—lymphatic system cancer	0.000859	0.0043	CcSEcCtD
Zafirlukast—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000853	0.00427	CcSEcCtD
Zafirlukast—Nausea—Mechlorethamine—lymphatic system cancer	0.00084	0.0042	CcSEcCtD
Zafirlukast—Hyperbilirubinaemia—Methotrexate—lymphatic system cancer	0.000837	0.00419	CcSEcCtD
Zafirlukast—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.000835	0.00418	CcSEcCtD
Zafirlukast—Jaundice—Mitoxantrone—lymphatic system cancer	0.000833	0.00417	CcSEcCtD
Zafirlukast—Haemoglobin—Carmustine—lymphatic system cancer	0.00083	0.00415	CcSEcCtD
Zafirlukast—Urticaria—Teniposide—lymphatic system cancer	0.000828	0.00414	CcSEcCtD
Zafirlukast—Haemorrhage—Carmustine—lymphatic system cancer	0.000825	0.00413	CcSEcCtD
Zafirlukast—Body temperature increased—Teniposide—lymphatic system cancer	0.000824	0.00412	CcSEcCtD
Zafirlukast—Abdominal pain—Teniposide—lymphatic system cancer	0.000824	0.00412	CcSEcCtD
Zafirlukast—Hypoaesthesia—Carmustine—lymphatic system cancer	0.000821	0.00411	CcSEcCtD
Zafirlukast—Dyspepsia—Fludarabine—lymphatic system cancer	0.000807	0.00404	CcSEcCtD
Zafirlukast—Sinusitis—Mitoxantrone—lymphatic system cancer	0.000802	0.00401	CcSEcCtD
Zafirlukast—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.000798	0.00399	CcSEcCtD
Zafirlukast—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000791	0.00396	CcSEcCtD
Zafirlukast—Fatigue—Fludarabine—lymphatic system cancer	0.00079	0.00395	CcSEcCtD
Zafirlukast—Hypoaesthesia—Vincristine—lymphatic system cancer	0.000784	0.00392	CcSEcCtD
Zafirlukast—Pain—Fludarabine—lymphatic system cancer	0.000784	0.00392	CcSEcCtD
Zafirlukast—Vasculitis—Methotrexate—lymphatic system cancer	0.00078	0.0039	CcSEcCtD
Zafirlukast—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.000771	0.00386	CcSEcCtD
Zafirlukast—Hypersensitivity—Teniposide—lymphatic system cancer	0.000768	0.00384	CcSEcCtD
Zafirlukast—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.000767	0.00384	CcSEcCtD
Zafirlukast—Hepatitis—Mitoxantrone—lymphatic system cancer	0.000767	0.00384	CcSEcCtD
Zafirlukast—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000764	0.00382	CcSEcCtD
Zafirlukast—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000755	0.00378	CcSEcCtD
Zafirlukast—Asthenia—Teniposide—lymphatic system cancer	0.000748	0.00374	CcSEcCtD
Zafirlukast—Malaise—Bleomycin—lymphatic system cancer	0.000742	0.00371	CcSEcCtD
Zafirlukast—Pruritus—Teniposide—lymphatic system cancer	0.000738	0.00369	CcSEcCtD
Zafirlukast—Body temperature increased—Fludarabine—lymphatic system cancer	0.000724	0.00362	CcSEcCtD
Zafirlukast—Diarrhoea—Teniposide—lymphatic system cancer	0.000713	0.00357	CcSEcCtD
Zafirlukast—Myalgia—Bleomycin—lymphatic system cancer	0.000701	0.00351	CcSEcCtD
Zafirlukast—Back pain—Carmustine—lymphatic system cancer	0.000695	0.00348	CcSEcCtD
Zafirlukast—Discomfort—Bleomycin—lymphatic system cancer	0.000692	0.00346	CcSEcCtD
Zafirlukast—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000675	0.00338	CcSEcCtD
Zafirlukast—Oedema—Bleomycin—lymphatic system cancer	0.000672	0.00336	CcSEcCtD
Zafirlukast—Infection—Bleomycin—lymphatic system cancer	0.000667	0.00334	CcSEcCtD
Zafirlukast—Back pain—Vincristine—lymphatic system cancer	0.000663	0.00332	CcSEcCtD
Zafirlukast—Vomiting—Teniposide—lymphatic system cancer	0.000663	0.00332	CcSEcCtD
Zafirlukast—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000658	0.00329	CcSEcCtD
Zafirlukast—Asthenia—Fludarabine—lymphatic system cancer	0.000657	0.00329	CcSEcCtD
Zafirlukast—Rash—Teniposide—lymphatic system cancer	0.000657	0.00329	CcSEcCtD
Zafirlukast—Dermatitis—Teniposide—lymphatic system cancer	0.000657	0.00329	CcSEcCtD
Zafirlukast—Headache—Teniposide—lymphatic system cancer	0.000653	0.00327	CcSEcCtD
Zafirlukast—Pruritus—Fludarabine—lymphatic system cancer	0.000648	0.00324	CcSEcCtD
Zafirlukast—Back pain—Mitoxantrone—lymphatic system cancer	0.000646	0.00323	CcSEcCtD
Zafirlukast—Diarrhoea—Fludarabine—lymphatic system cancer	0.000627	0.00314	CcSEcCtD
Zafirlukast—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00062	0.0031	CcSEcCtD
Zafirlukast—Nausea—Teniposide—lymphatic system cancer	0.000619	0.0031	CcSEcCtD
Zafirlukast—Hepatic failure—Methotrexate—lymphatic system cancer	0.000615	0.00308	CcSEcCtD
Zafirlukast—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000612	0.00306	CcSEcCtD
Zafirlukast—Myalgia—Carmustine—lymphatic system cancer	0.000612	0.00306	CcSEcCtD
Zafirlukast—Malaise—Mitoxantrone—lymphatic system cancer	0.000602	0.00301	CcSEcCtD
Zafirlukast—Oedema—Carmustine—lymphatic system cancer	0.000586	0.00293	CcSEcCtD
Zafirlukast—Myalgia—Vincristine—lymphatic system cancer	0.000584	0.00292	CcSEcCtD
Zafirlukast—Infection—Carmustine—lymphatic system cancer	0.000583	0.00291	CcSEcCtD
Zafirlukast—Vomiting—Fludarabine—lymphatic system cancer	0.000583	0.00291	CcSEcCtD
Zafirlukast—Rash—Fludarabine—lymphatic system cancer	0.000578	0.00289	CcSEcCtD
Zafirlukast—Dermatitis—Fludarabine—lymphatic system cancer	0.000577	0.00289	CcSEcCtD
Zafirlukast—Pain—Bleomycin—lymphatic system cancer	0.000575	0.00287	CcSEcCtD
Zafirlukast—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000574	0.00287	CcSEcCtD
Zafirlukast—Headache—Fludarabine—lymphatic system cancer	0.000574	0.00287	CcSEcCtD
Zafirlukast—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000569	0.00285	CcSEcCtD
Zafirlukast—Myalgia—Mitoxantrone—lymphatic system cancer	0.000569	0.00285	CcSEcCtD
Zafirlukast—Discomfort—Mitoxantrone—lymphatic system cancer	0.000562	0.00281	CcSEcCtD
Zafirlukast—Oedema—Vincristine—lymphatic system cancer	0.00056	0.0028	CcSEcCtD
Zafirlukast—Infection—Vincristine—lymphatic system cancer	0.000556	0.00278	CcSEcCtD
Zafirlukast—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000554	0.00277	CcSEcCtD
Zafirlukast—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000548	0.00274	CcSEcCtD
Zafirlukast—Oedema—Mitoxantrone—lymphatic system cancer	0.000545	0.00273	CcSEcCtD
Zafirlukast—Nausea—Fludarabine—lymphatic system cancer	0.000544	0.00272	CcSEcCtD
Zafirlukast—Infection—Mitoxantrone—lymphatic system cancer	0.000542	0.00271	CcSEcCtD
Zafirlukast—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000534	0.00267	CcSEcCtD
Zafirlukast—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000534	0.00267	CcSEcCtD
Zafirlukast—Urticaria—Bleomycin—lymphatic system cancer	0.000534	0.00267	CcSEcCtD
Zafirlukast—Body temperature increased—Bleomycin—lymphatic system cancer	0.000531	0.00266	CcSEcCtD
Zafirlukast—Insomnia—Carmustine—lymphatic system cancer	0.00053	0.00265	CcSEcCtD
Zafirlukast—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.00051	0.00255	CcSEcCtD
Zafirlukast—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00051	0.00255	CcSEcCtD
Zafirlukast—Insomnia—Vincristine—lymphatic system cancer	0.000506	0.00253	CcSEcCtD
Zafirlukast—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000506	0.00253	CcSEcCtD
Zafirlukast—Pain—Carmustine—lymphatic system cancer	0.000501	0.00251	CcSEcCtD
Zafirlukast—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000497	0.00249	CcSEcCtD
Zafirlukast—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000495	0.00248	CcSEcCtD
Zafirlukast—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000483	0.00242	CcSEcCtD
Zafirlukast—Feeling abnormal—Carmustine—lymphatic system cancer	0.000483	0.00242	CcSEcCtD
Zafirlukast—Fatigue—Vincristine—lymphatic system cancer	0.000483	0.00241	CcSEcCtD
Zafirlukast—Asthenia—Bleomycin—lymphatic system cancer	0.000482	0.00241	CcSEcCtD
Zafirlukast—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00048	0.0024	CcSEcCtD
Zafirlukast—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00048	0.0024	CcSEcCtD
Zafirlukast—Pain—Vincristine—lymphatic system cancer	0.000479	0.0024	CcSEcCtD
Zafirlukast—Pruritus—Bleomycin—lymphatic system cancer	0.000475	0.00238	CcSEcCtD
Zafirlukast—Eosinophilia—Methotrexate—lymphatic system cancer	0.000473	0.00237	CcSEcCtD
Zafirlukast—Fatigue—Mitoxantrone—lymphatic system cancer	0.00047	0.00235	CcSEcCtD
Zafirlukast—Pain—Mitoxantrone—lymphatic system cancer	0.000466	0.00233	CcSEcCtD
Zafirlukast—Abdominal pain—Carmustine—lymphatic system cancer	0.000464	0.00232	CcSEcCtD
Zafirlukast—Body temperature increased—Carmustine—lymphatic system cancer	0.000464	0.00232	CcSEcCtD
Zafirlukast—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000458	0.00229	CcSEcCtD
Zafirlukast—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000458	0.00229	CcSEcCtD
Zafirlukast—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000449	0.00225	CcSEcCtD
Zafirlukast—Neutropenia—Methotrexate—lymphatic system cancer	0.000447	0.00223	CcSEcCtD
Zafirlukast—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000446	0.00223	CcSEcCtD
Zafirlukast—Abdominal pain—Vincristine—lymphatic system cancer	0.000443	0.00221	CcSEcCtD
Zafirlukast—Body temperature increased—Vincristine—lymphatic system cancer	0.000443	0.00221	CcSEcCtD
Zafirlukast—Urticaria—Mitoxantrone—lymphatic system cancer	0.000433	0.00217	CcSEcCtD
Zafirlukast—Hypersensitivity—Carmustine—lymphatic system cancer	0.000432	0.00216	CcSEcCtD
Zafirlukast—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000431	0.00216	CcSEcCtD
Zafirlukast—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000431	0.00216	CcSEcCtD
Zafirlukast—Vomiting—Bleomycin—lymphatic system cancer	0.000427	0.00214	CcSEcCtD
Zafirlukast—Rash—Bleomycin—lymphatic system cancer	0.000424	0.00212	CcSEcCtD
Zafirlukast—Dermatitis—Bleomycin—lymphatic system cancer	0.000423	0.00212	CcSEcCtD
Zafirlukast—Asthenia—Carmustine—lymphatic system cancer	0.000421	0.00211	CcSEcCtD
Zafirlukast—Hypersensitivity—Vincristine—lymphatic system cancer	0.000412	0.00206	CcSEcCtD
Zafirlukast—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000402	0.00201	CcSEcCtD
Zafirlukast—Asthenia—Vincristine—lymphatic system cancer	0.000402	0.00201	CcSEcCtD
Zafirlukast—Diarrhoea—Carmustine—lymphatic system cancer	0.000401	0.00201	CcSEcCtD
Zafirlukast—Nausea—Bleomycin—lymphatic system cancer	0.000399	0.002	CcSEcCtD
Zafirlukast—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000397	0.00199	CcSEcCtD
Zafirlukast—Asthenia—Mitoxantrone—lymphatic system cancer	0.000391	0.00196	CcSEcCtD
Zafirlukast—Dizziness—Carmustine—lymphatic system cancer	0.000388	0.00194	CcSEcCtD
Zafirlukast—Haemoglobin—Methotrexate—lymphatic system cancer	0.000384	0.00192	CcSEcCtD
Zafirlukast—Diarrhoea—Vincristine—lymphatic system cancer	0.000383	0.00192	CcSEcCtD
Zafirlukast—Haemorrhage—Methotrexate—lymphatic system cancer	0.000382	0.00191	CcSEcCtD
Zafirlukast—Hepatitis—Methotrexate—lymphatic system cancer	0.000382	0.00191	CcSEcCtD
Zafirlukast—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000373	0.00187	CcSEcCtD
Zafirlukast—Vomiting—Carmustine—lymphatic system cancer	0.000373	0.00187	CcSEcCtD
Zafirlukast—Dizziness—Vincristine—lymphatic system cancer	0.00037	0.00185	CcSEcCtD
Zafirlukast—Rash—Carmustine—lymphatic system cancer	0.00037	0.00185	CcSEcCtD
Zafirlukast—Dermatitis—Carmustine—lymphatic system cancer	0.000369	0.00185	CcSEcCtD
Zafirlukast—Headache—Carmustine—lymphatic system cancer	0.000367	0.00184	CcSEcCtD
Zafirlukast—Vomiting—Vincristine—lymphatic system cancer	0.000356	0.00178	CcSEcCtD
Zafirlukast—Rash—Vincristine—lymphatic system cancer	0.000353	0.00177	CcSEcCtD
Zafirlukast—Dermatitis—Vincristine—lymphatic system cancer	0.000353	0.00176	CcSEcCtD
Zafirlukast—Headache—Vincristine—lymphatic system cancer	0.000351	0.00175	CcSEcCtD
Zafirlukast—Nausea—Carmustine—lymphatic system cancer	0.000348	0.00174	CcSEcCtD
Zafirlukast—Vomiting—Mitoxantrone—lymphatic system cancer	0.000347	0.00173	CcSEcCtD
Zafirlukast—Rash—Mitoxantrone—lymphatic system cancer	0.000344	0.00172	CcSEcCtD
Zafirlukast—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000343	0.00172	CcSEcCtD
Zafirlukast—Headache—Mitoxantrone—lymphatic system cancer	0.000342	0.00171	CcSEcCtD
Zafirlukast—Nausea—Vincristine—lymphatic system cancer	0.000333	0.00166	CcSEcCtD
Zafirlukast—Nausea—Mitoxantrone—lymphatic system cancer	0.000324	0.00162	CcSEcCtD
Zafirlukast—Back pain—Methotrexate—lymphatic system cancer	0.000322	0.00161	CcSEcCtD
Zafirlukast—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000309	0.00155	CcSEcCtD
Zafirlukast—Malaise—Methotrexate—lymphatic system cancer	0.0003	0.0015	CcSEcCtD
Zafirlukast—Myalgia—Methotrexate—lymphatic system cancer	0.000283	0.00142	CcSEcCtD
Zafirlukast—Arthralgia—Methotrexate—lymphatic system cancer	0.000283	0.00142	CcSEcCtD
Zafirlukast—Discomfort—Methotrexate—lymphatic system cancer	0.00028	0.0014	CcSEcCtD
Zafirlukast—Infection—Methotrexate—lymphatic system cancer	0.00027	0.00135	CcSEcCtD
Zafirlukast—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000266	0.00133	CcSEcCtD
Zafirlukast—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000247	0.00124	CcSEcCtD
Zafirlukast—Insomnia—Methotrexate—lymphatic system cancer	0.000246	0.00123	CcSEcCtD
Zafirlukast—Dyspepsia—Methotrexate—lymphatic system cancer	0.000239	0.0012	CcSEcCtD
Zafirlukast—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000235	0.00117	CcSEcCtD
Zafirlukast—Fatigue—Methotrexate—lymphatic system cancer	0.000234	0.00117	CcSEcCtD
Zafirlukast—Pain—Methotrexate—lymphatic system cancer	0.000232	0.00116	CcSEcCtD
Zafirlukast—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000224	0.00112	CcSEcCtD
Zafirlukast—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000222	0.00111	CcSEcCtD
Zafirlukast—Urticaria—Methotrexate—lymphatic system cancer	0.000216	0.00108	CcSEcCtD
Zafirlukast—Abdominal pain—Methotrexate—lymphatic system cancer	0.000215	0.00107	CcSEcCtD
Zafirlukast—Body temperature increased—Methotrexate—lymphatic system cancer	0.000215	0.00107	CcSEcCtD
Zafirlukast—Hypersensitivity—Methotrexate—lymphatic system cancer	0.0002	0.001	CcSEcCtD
Zafirlukast—Asthenia—Methotrexate—lymphatic system cancer	0.000195	0.000975	CcSEcCtD
Zafirlukast—Pruritus—Methotrexate—lymphatic system cancer	0.000192	0.000962	CcSEcCtD
Zafirlukast—Diarrhoea—Methotrexate—lymphatic system cancer	0.000186	0.00093	CcSEcCtD
Zafirlukast—Dizziness—Methotrexate—lymphatic system cancer	0.00018	0.000899	CcSEcCtD
Zafirlukast—Vomiting—Methotrexate—lymphatic system cancer	0.000173	0.000864	CcSEcCtD
Zafirlukast—Rash—Methotrexate—lymphatic system cancer	0.000171	0.000857	CcSEcCtD
Zafirlukast—Dermatitis—Methotrexate—lymphatic system cancer	0.000171	0.000856	CcSEcCtD
Zafirlukast—Headache—Methotrexate—lymphatic system cancer	0.00017	0.000851	CcSEcCtD
Zafirlukast—Nausea—Methotrexate—lymphatic system cancer	0.000161	0.000807	CcSEcCtD
